WHAT IS CLAIMED IS:

1. An anti-craving medication for administration to the body of an individual suffering from substance abuse, said medication comprising:

i) a first component comprising of the following agents: selected forms of selected amino-acids,

ii) a second component comprising of the following agents: selected forms of selected vitamins, and

iii) a third component comprising of the following agents: selected forms of selected minerals,

said agents being selected for their combined ability to reduce craving, and

said agents further being selected so as to allow efficient use of the medication by such body of an individual suffering from substance abuse.

2. The anti-craving medication of claim 1, wherein said selection of said agents so as to allow efficient use of the medication by the body of an individual suffering from substance abuse further comprises:

selection based upon said agents' combined ability to promote crossing of the blood/brain barrier by at least one of said agents.

3. The anti-craving medication of claim 1, wherein said selection of said agents so as to allow efficient use of the medication by the body of an individual suffering from substance

abuse further comprises:

selection based upon said agents' abilities to promote liver by-pass by at least one of said agents.

4. The anti-craving medication of claim 1, wherein said selection of said agents so as to allow efficient use of the medication by the body of an individual suffering from substance abuse further comprises:

selection based upon said agents' abilities to promote stomach lining by-pass by at least one of said agents.

5. The anti-craving medication of claim 1, wherein said selection of said agents so as to allow efficient use of the medication by the body of an individual suffering from substance abuse further comprises:

selection based upon said agents' combined ability to promote intestinal lining by-pass by at least one of said agents.

6. The anti-craving medication of claim 1, wherein said selection of said agents so as to allow efficient use of the medication by the body of an individual suffering from substance abuse further comprises:

selection based upon said agents' combined ability to promote,

i) crossing of the blood/brain barrier by at least one of said agents,

ii) liver by-pass by at least one of said agents,

iii) stomach lining by-pass by at least one of said agents, and

iv) intestinal lining by-pass by at least one of said agents.

7. The anti-craving medication of claim 1, wherein said selection of forms of selected amino-acids further comprises:

preferentially selecting forms of said selected amino-acids which easily cross the blood/brain barrier.

8. The anti-craving medication of claim 7, wherein said selection of forms of selected amino-acids further comprises:

preferentially selecting isomers of said selected amino-acids having the ability to easily cross the blood/brain barrier.

9. The anti-craving medication of claim 1, wherein said first component further comprises:

at least four amino-acids selected from the group consisting of: D-phenylalanine, L-phenylalanine, L-tyrosine, L-tryptophan and L-glutathione.

10. The anti-craving medication of claim 1, wherein said selection of said forms of said minerals further comprises:

selecting molecular forms of the minerals having small size.

11. The anti-craving medication of claim 1, wherein said selection of said forms of said minerals further comprises:

selecting mineral forms which are water soluble.

12. The anti-craving medication of claim 1, wherein said selection of said forms of said minerals further comprises:

selecting mineral forms which are cellularly active.

13. The anti-craving medication of claim 1, wherein said selection of said forms of said minerals further comprises:

selectively avoiding usage of forms of said minerals which release calcium while being metabolized, whereby efficient use of the medication by such body of an individual suffering from substance abuse is promoted.

14. The anti-craving medication of claim 1, wherein said selection of said forms of said minerals further comprises:

selecting minerals in sulfate forms.

15. The anti-craving medication of claim 1, wherein said selection of said forms of said minerals further comprises:

selecting non-chelate mineral forms.

16. The anti-craving medication of claim 1, wherein said third component further comprises:

at least five members selected from the group consisting of: magnesium chloride, zinc sulfate, cupric sulfate, manganese sulfate, chromic chloride, sodium selenite.

17. The anti-craving medication of claim 1, wherein said agents selected so as to allow efficient use of the medication by the body of an individual suffering from substance abuse further comprises:

selecting vitamin forms which are water soluble.

18. The anti-craving medication of claim 1, wherein said agents selected so as to allow efficient use of the medication by the body of an individual suffering from substance abuse further comprises:

selecting vitamin forms which are cellularly active.

19. The anti-craving medication of claim 1, wherein said second component further comprises:

riboflavin-5-phosphate sodium, whereby efficient use of the medication by such body of an individual suffering from substance abuse is promoted.

20. The anti-craving medication of claim 1, wherein said third component further comprises:

methylcobolamin, whereby efficient use of the medication by such body of an individual suffering from substance abuse is promoted.

21. The anti-craving medication of claim 1, wherein said third component further comprises:

at least four members selected from the group consisting of: folic acid sodium salt, methylcobolamin, beet-source ascorbic acid sodium salt, thiamine hydrochloride, pyridoxal-5-phosphate monohydrate, riboflavin-5-phosphate sodium, niacinamide, dexpanthenol, and inositol.

22. The anti-craving medication of claim 1, wherein said selection of said agents of said first component further comprises:

selecting said agents so as to allow said first component to be a single vial of medication suitable for intravenous administration.

23. The anti-craving medication of claim 1, wherein said selection of said agents of said second component further comprises:

selecting said agents so as to allow said second component to be a single vial of medication suitable for intravenous administration.

24. The anti-craving medication of claim 1, wherein said selection of said agents of said third component further comprises:

selecting said agents so as to allow said third component to be a single vial of medication suitable for intravenous administration.

25. The anti-craving medication of claim 1, wherein said selection of said agents of each of said first, second and third components further comprises:

selecting said agents so as to allow each of said first, second and third components to be a single vial of medication suitable for intravenous administration, whereby a total of only three vials must be administered to such patient suffering from substance abuse.

26. The anti-craving medication of claim 25, wherein each of said components is introduced into a saline solution.

27. The anti-craving medication of claim 26, wherein said saline solution is adjusted to maintain an osmolarity in the range between approximately 210 mOsm/l and approximately 300 mOsm/l, preferably approximately 295 mOsm/l.

28. A method of treating substance abuse comprising:

administering the medication of claim 1 to such individual suffering from substance abuse disorder, in a dosage sufficient to reduce craving by such individual for the abused substance.

29. An anti-craving medication for administration to the body of an individual suffering from substance abuse, said medication comprising:

i) a first component comprising of the following agents: selected forms of selected amino-acids,

ii) a second component comprising of the following agents: selected forms of selected vitamins, and

iii) a third component comprising of the following agents: selected forms of selected

minerals,

said agents being selected for their combined ability to reduce craving, and

said agents further being selected so as to require minimal metabolic processing of said agents by such body of individual suffering from substance abuse prior to the agents taking effect in the brain of such individual.

30. A method of administering an anti-craving medication to the body of an individual suffering from substance abuse, said method comprising:

administering a saline solution to the patient via intravenous drip, and

supplying such anti-craving medication in said intravenous drip.

31. The method of administering an anti-craving medication of claim 30, further comprising:

initially supplying a short-term bolus of such anti-craving medication via direct injection.

32. The method of administering an anti-craving mediation of claim 30, wherein said mid-term intravenous drip further comprises:

continuing said administration for a period of time greater than approximately two minutes and less than approximately three hours.

33. The method of administering an anti-craving mediation of claim 30, wherein said mid-term intravenous drip further comprises:

continuing said administration for a period of time greater than approximately one hour

and less than approximately three hours.

34. An anti-craving medication comprising:

L-glutathione.

35. The anti-craving medication according to claim 34, further comprising:

L-glutathione having the sulfur molecule removed.

36. The anti-craving medication according to claim 34, further comprising:

L-glutathione having a PH in the range from approximately 6.4 to approximately 7.2.

37. An anti-craving medication for administration to the bodies of patients suffering from substance abuse, wherein said anti-craving medication comprising:

at least one mineral possessing sodium in an amount sufficient to reduce the need for such bodies of patients suffering from substance abuse to metabolize said vitamins by addition of sodium, and

at least one vitamin possessing sodium in an amount sufficient to reduce the need for such bodies of patients suffering from substance abuse to metabolize said vitamins by addition of sodium.

38. An anti-craving medication comprising:

at least one member selected from the group comprising: riboflavin-5-phosphate sodium,

dexpanthenol, niacinamide, folic acid sodium salt, methylcobolamin, inositol, and beet-source ascorbic acid sodium salt.

39. An improved anti-craving medication having a plurality of active agents wherein the improvement consists of:

selecting agents based upon their ability to by-pass metabolic processes.